RESUMEN
OBJECTIVE: Black women's experiences of gendered racism have implications for their mental health. The present study tested the associations between gendered racism, social support, and depression, then investigated whether gendered racial centrality buffered the impact of gendered racism on mental health outcomes. METHOD: Data from 237 Black college women (Mage = 22.04, SD = 4.02 years) were collected using an online survey, assessing gendered racism, social support, depression, and gendered racial identity. RESULTS: We found that social support mediated (but did not moderate) the association between gendered racism and depression: More gendered racism was associated with decreased support, and consequently more depression. Also, higher gendered racial centrality buffered the indirect effect of gendered racism on greater depression via lower social support. CONCLUSION: Our results further illustrate the detrimental effect of gendered racism on Black women, while also illuminating areas for intervention useful for this group. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Asunto(s)
Racismo , Adulto , Negro o Afroamericano , Población Negra , Depresión , Femenino , Humanos , Apoyo Social , Adulto JovenRESUMEN
Many individuals with post-traumatic stress disorder (PTSD) experience persistent symptoms despite pharmacological treatment with antidepressants. Several open-label monotherapy and adjunctive studies have suggested that aripiprazole (a second-generation antipsychotic) may have clinical utility in PTSD. However, there have been no randomized placebo-controlled trials of aripiprazole use for PTSD. We thus conducted a pilot randomized controlled trial of adjunctive aripiprazole versus placebo among Veterans with chronic PTSD serving in the US military since 11 September 2001 to assess the feasibility, safety, tolerability, and therapeutic potential of aripiprazole. Sixteen Veterans were randomized, and 14 completed at least 4 weeks of the study; 12 completed the entire 8-week trial. Outcome measures included the Clinician-Administered PTSD Scale (CAPS), PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores. Aripiprazole was well-tolerated in this cohort, and improvements in CAPS, PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores were as hypothesized. Although CAPS change scores did not reach statistical significance, aripiprazole outperformed placebo by 9 points on the CAPS in the last observation carried forward analysis compared with the placebo group (n = 7 per group), and by 20 points in the group randomized to aripiprazole that completed the entire study (n = 5) compared with the placebo group (n = 7). Results suggest promise for aripiprazole as an adjunctive strategy for the treatment of PTSD.